Conexeu Sciences holder reports 5.5% ownership stake
Conexeu Sciences Inc. received a Schedule 13G reporting that OnePointTwo Capital Ventures II LLC, a Delaware limited liability company, beneficially owns 1,484,240 shares of the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Conexeu Sciences Inc. received a Schedule 13G reporting that OnePointTwo Capital Ventures II LLC, a Delaware limited liability company, beneficially owns 1,484,240 shares of the company’s common stock. This represents 5.5% of the class as of June 30, 2026.
OnePointTwo Capital Ventures II LLC reports sole voting power and sole dispositive power over all 1,484,240 shares, with no shared voting or dispositive power. The certification section is marked not applicable, and the report is signed by Lynn Sebastian Purcell as Managing Member of OnePointTwo Capital Performance LLC, the managing member of the reporting entity.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole voting power financial
sole dispositive power financial
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Conexeu Sciences Inc. (CNXU) does OnePointTwo Capital Ventures II LLC own?
What dispositive power does OnePointTwo Capital Ventures II LLC report over Conexeu Sciences Inc. (CNXU) stock?
Who signed the Schedule 13G filed for Conexeu Sciences Inc. (CNXU)?
Where is Conexeu Sciences Inc.’s principal executive office located according to the Schedule 13G?
AI-generated analysis. How Rhea-AI works. Not financial advice.